Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28224660 | 0.98 | KMT2A (0.35) | KMT2AMEN1PTGS1PTGS2NT5E | |
| SCHEMBL18228 | 0.81 | ALDH1A1 (0.36) | KMT2AMEN1CYP19A1CCNE1CDK2 | |
| SCHEMBL5152395 | 0.81 | CCNE1 (0.38) | KMT2AMEN1CYP19A1CCNE1CDK2 | |
| SCHEMBL6821240 | 0.81 | CCNE1 (0.50) | CCNE1CDK2CDK5CDK5R1CA1 | |
| SCHEMBL10753718 | 0.74 | CCNE1 (0.32) | KMT2AMEN1CYP19A1CCNE1CDK2 | |
| SCHEMBL1457080 | 0.71 | — | — | |
| Sulfuric Acid SCHEMBL2943116 | 0.69 | CYP19A1 (0.62) | KMT2AMEN1CYP19A1CA1CA2 | |
| SCHEMBL6282064 | 0.69 | CES2 (0.43) | CA2LMNAALDH1A1 | |
| SCHEMBL9005006 | 0.69 | PTPRC (0.46) | KMT2AMEN1CYP19A1GAAL3MBTL1 | |
| SCHEMBL2016370 | 0.69 | PTPRC (0.46) | KMT2AMEN1CYP19A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| US-10655091-B2 | Thiophene azo dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190345415-A1 | THIOPHENE AZO DYES AND LAUNDRY CARE COMPOSITIONS CONTAINING THE SAME | PROCTER & GAMBLE (US) | 2019-11-14 | — | — | US | disclosed |
| US-10435651-B2 | Thiophene azo dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180066215-A1 | THIOPHENE AZO DYES AND LAUNDRY CARE COMPOSITIONS CONTAINING THE SAME | PROCTER & GAMBLE (US) | 2018-03-08 | — | — | US | disclosed |
| US-9752104-B2 | Thiophene AZO carboxylate dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9567465-B2 | Thiophene azo carboxylate dyes and laundry care compositions containing the same | MILLIKEN & COMPANY (US) | 2017-02-14 | — | — | US | disclosed |
| US-9556337-B2 | Thiophene azo dyes and laundry care compositions containing the same | MILLIKEN & COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| CN-1675225-A | Macrocyclic pyrimidine compounds, process for their preparation and their use as pharmaceuticals | SCHERING AG (DE) | 2005-09-28 | — | — | CN | disclosed |
| CN-1665802-A | Bisarylsulfonamide compounds and their use in cancer therapy | CYCLACEL LTD (GB) | 2005-09-07 | — | — | CN | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | SCHERING AG (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | CCNK, CDK2, CDK1 | KMT2A 3155/4885MEN1 2527/4885PTGS1 501/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | KMT2A 1243/4885MEN1 2662/4885PTGS1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.